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Abstract
Clinical evaluation and mutation analysis was performed in 51 consecutive pro-
bands with severe eye malformations – anophthalmia and/or severe microph-
thalmia – seen in a single specialist ophthalmology center. The mutation
analysis consisted of bidirectional sequencing of the coding regions of SOX2,
OTX2, PAX6 (paired domain), STRA6, BMP4, SMOC1, FOXE3, and RAX, and
genome-wide array-based copy number assessment. Fifteen (29.4%) of the 51
probands had likely causative mutations affecting SOX2 (9/51), OTX2 (5/51),
and STRA6 (1/51). Of the cases with bilateral anophthalmia, 9/12 (75%) were
found to be mutation positive. Three of these mutations were large genomic
deletions encompassing SOX2 (one case) or OTX2 (two cases). Familial inheri-
tance of three intragenic, plausibly pathogenic, and heterozygous mutations was
observed. An unaffected carrier parent of an affected child with an identified
OTX2 mutation confirmed the previously reported nonpenetrance for this dis-
order. Two families with SOX2 mutations demonstrated a parent and child
both with significant but highly variable eye malformations. Heterozygous loss-
of-function mutations in SOX2 and OTX2 are the most common genetic
pathology associated with severe eye malformations and bi-allelic loss-of-
function in STRA6 is confirmed as an emerging cause of nonsyndromal eye
malformations.
Introduction
Severe eye malformations are a clinically important but rare
group of developmental disorders with a combined live
birth prevalence of 1 per 10,000 (Shah et al. 2011, 2012).
Anophthalmia is the absence of the globe in presence of
ocular adnexa. An extremely rare subgroup is termed
true anophthalmia, which is associated with the complete
absence of neuroectodermal tissue in the orbit. The more
common presentation is termed “clinical anophthalmia.”
In this form, no ocular tissue is visible on examination
(Duke-Elder 1964) but remnants of the optic vesicle, mus-
cle or optic nerve tissue or cysts are detected by orbital
magnetic resonance imaging (MRI) or ultrasonography
(for an example see Fig. 3). Microphthalmia can be
defined as an eye with an axial length of <19 mm in a
1-year-old child or <21 mm in an adult (2 SD below nor-
mal; Weiss et al. 1989a,b). Microphthalmia can occur
without (simple type) or with anterior and or posterior
segment dysgenesis (complex type). Ocular coloboma,
complex microphthalmia, and both clinical and true
anophthalmia probably present a continuum of malforma-
tion severity.
Anophthalmia and complex microphthalmia are etiolog-
ically heterogeneous. Causative mutations are identified in
many different genes including SOX2 (Fantes et al. 2003),
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OTX2 (Ragge et al. 2005a), PAX6 (Glaser et al. 1994),
STRA6 (Pasutto et al. 2007), FOXE3 (Reis et al. 2010),
RAX (Voronina et al. 2004; Lequeux et al. 2008), SMOC1
(Abouzeid et al. 2011; Okada et al. 2011; Rainger et al.
2011), and BMP4 (Bakrania et al. 2008). Heterozygous
loss-of-function mutations in either SOX2 account for
about 15% of cases with severe bilateral eye developmental
defects (Bardakjian et al. 1993; FitzPatrick 1993; Ragge
et al. 2005b) or OTX2 mutations ranging between 2% and
8% of the investigated cohort (Ragge et al. 2005a; Wyatt
et al. 2008; Schilter et al. 2011). Heterozygous, loss-of-
function mutations in the OTX2 gene commonly occur de
novo in affected children but in 35% of cases the mutation
is inherited from a completely normal parent (Ragge et al.
2005a; Schilter et al. 2011). SOX2 mutations almost always
occur de novo and appear to be fully penetrant with all
reports of sibling recurrence associated with detectable
mosaicism in the mother (Faivre et al. 2006; Chassaing
et al. 2007; Schneider et al. 2008).
Here, we describe a clinical evaluation and comprehen-
sive mutation analysis in 51 probands with microphthal-
mia and/or anophthalmia seen in a single specialist
ophthalmology center. Genome-wide oligonucleotide
array-based comparative genomic hybridization (aCGH)
was performed on each proband together with sequencing
of the coding regions of SOX2, OTX2, PAX6 (paired
domain), STRA6, BMP4, SMOC1, FOXE3, and RAX. We
identified different mutations in the 15/51 (29.4%) of the
probands in SOX2 (9/51), OTX2 (5/51), and STRA6 (1/
51). The mutation-positive individuals were more likely to
have bilateral rather than unilateral eye disease (13:3).
Indeed 9/12 (75%) of the cases with bilateral anophthal-
mia (BA) were found to be mutation positive. Familial
inheritance of a plausibly pathogenic heterozygous muta-
tion was seen for both SOX2 (two families) and OTX2
(one family). In the latter family, an unaffected carrier
parent of an affected child with an identified OTX2 muta-
tion was consistent with the previously reported nonpene-
trance for this disorder. For SOX2, both families
demonstrated full penetrance but variable expressivity with
parents and children associated with SOX2 mutation each
having significant eye malformations.
Methods
Case ascertainment
Patients and parents of children with unilateral anopht-
almia (UA) or BA or microphthalmia referred to the
Department of Ophthalmology at the University of Ro-
stock for evaluation of surgical therapy with orbital or
socket expander were invited to participate in this study.
The study was approved by the Ethics board of the Univer-
sity of Rostock (reference A 2008-62) and the U.K. Multi-
regional Ethics Committee (Reference: 06/MRE00/76).
Phenotype assessment
All patients and available parents received a comprehensive
eye examination including dilated fundus examination.
Birth history, extraocular anomalies, and developmental
data with emphasis on speech and motor development
were extracted from medical reports and parent interview.
Sleep abnormalities were evaluated using the sleep distur-
bance scale for children through parent interviewing
(Eitner et al. 2007). Z-scores for height, weight, and head
circumference were calculated using the LMS method
based on data from U.K. children (Cole et al. 1998).
Cerebral MRI was reassessed if available. The analysis
of intracerebral abnormalities was focused on corpus
callosum, hypothalamus, and hippocampus integrity
based on published data of patients with microphthalmia
or anophthalmia (Leichtman et al. 1994; Warburg et al.
1997; Arnold et al. 2003; Ragge et al. 2005a,b; Makhoul
et al. 2007; Kelberman et al. 2008; Schneider et al. 2008;
Tajima et al. 2009). Agenesis of the corpus callosum
refers to complete absence whereas hypoplasia refers to a
fully formed corpus callosum that is thinner than
expected for age. Results of previous image evaluation
were included in the study if original MRIs were not
available.
Intragenic mutation analysis
Genomic DNA was whole genome amplified using
GenomiPhi V2 DNA Amplification Kit (GE Healthcare
Life Sciences, Pittsburg, PA) prior to mutation screening.
To ensure a complete dataset, all eight genes were screened
in all affected individuals regardless of whether a plausibly
pathogenic mutation had been detected. Identified muta-
tions were validated using genomic DNA that had not
been whole genome amplified. For each gene, the ampli-
cons encompassing the coding exons and the intronic
splice junctions were designed using ExonPrimer or by
manual means. Full methods and oligonucleotide
sequences are available on request. Each amplicon was
sequenced on the ABI 3730 DNA Analyzer (Applied Bio-
systems, Foster City, CA) and the results were analyzed
with Mutation Surveyor v3.30 (SoftGenetics, State College,
PA). The genomic sequence identifiers for each gene ana-
lyzed are as follows: SOX2, NT_005612.15 GI:88966845;
OTX2, NT_026437.11 GI:51493278; PAX6, NC_000011.9
GI:224589802; STRA6, NG_009207.1 GI:219275560; BMP4,
NG_009215.1 GI:219521814; SMOC1, NC_000014.8 GI:
224589805; FOXE3, NG_016192.1 GI:281182531; and RAX,
NG_013031.1 GI:260655998.
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In silico analysis
Assessment of the pathogenic potential of the missense
mutations used different bioinformatics approaches. Poly-
Phen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://
sift.jcvi.org), and ALIGN-GVGD (http://agvgd.iarc.fr/
agvgd_input.php) use different algorithms to produce a
combined score based on a multispecies alignment and
the biophysical characteristics of the altered amino acids
(Tavtigian et al. 2006; Kumar et al. 2009; Adzhubei et al.
2010). Mutation Taster (http://www.mutationtaster.org/)
uses a Bayes Classifier that was trained on large sets of
pathological and benign amino acid substitutions. The
possible effect of one of the missense mutation on splice
site function used different prediction algorithms on the
mutant and wild-type allele implemented online using
SSF (http://www.umd.be/searchSpliceSite.html), MaxEnt
(Yeo and Burge 2004), and HSF (http://www.umd.be/
HSF/). These algorithms were implemented via the Alamut
package (Interactive Biosoftware, San Diego, CA). The
haploinsufficiency (HI) score was calculated manually
using the BED format dataset from the original report
(Huang et al. 2010) loaded as a custom track into the
UCSC Genome Browser (http://genome.ucsc.edu/).
Array-based comparative genomic
hybridization
Genome-wide analysis of DNA copy number aberrations
was carried out using the Roche Nimblegen 12X135k
whole-genome array (median probe spacing of approxi-
mately 12 kb) according to the manufacturer’s instruc-
tions, modified as follows: 250–800 ng of genomic DNA
from patient and sex-matched control samples (pool of five
male or female samples) was labeled overnight followed by
hybridization for 72 h. After washing, slides were scanned
using the Roche MS200 scanner, and analyzed using the
software NimbleScan (Roche Nimblegen, Madison, WI).
The CGH-segMNT module of NimbleScan was used for
the analysis with a minimum segment length of five
probes and an averaging window of 130 kb. Results were
compared with the Database of Genomic Variants (http://
projects.tcag.ca/variations) and polymorphic copy number
variation excluded. Deletions of the OTX2 gene were con-
firmed using the Roche Nimblegen 3X720k whole-genome
array (median probe spacing of approximately 2.5 kb) as
described above, with an averaging window of 20 kb.
Fluorescence in situ hybridization
Deletion of the SOX2 gene was confirmed by fluorescence
in situ hybridization (FISH). Metaphase chromosomes
were prepared from the patient lymphocytes as described
elsewhere (Weier et al. 1991). The BAC clone RP11-
43F17, which spans SOX2, was selected from the UCSC
Human Genome Browser (http://genome.ucsc.edu) and
the probe was labeled with biotin-16-dUTP (Roche, Basel,
Switzerland) by nick translation (Fantes et al., 2008). Fol-
lowing hybridization, slides were mounted with a drop of
Vectorshield antifadent containing DAPI (Sigma Aldrich,
St Louis, MO). Antibody detection was carried out by
fluorescent microscopy using a Zeiss Axioscop micro-
scope. Images were collected using a cooled CCD (charged
coupled device) camera (Smart-Capture software).
Results
Summary of cohort and mutation analysis
results
Fifty-one unrelated probands were enrolled in the study.
Inclusion of mutation-positive parents gives a total of 54
individuals (Table 1). One of these carrier parents did
not show any ocular abnormalities but is included as a
“case.” The male:female ratio was 24:30. Of the 53
affected cases, 42 had anophthalmia (unilateral:bilat-
eral = 30:12), 10 had severe microphthalmia (unilateral:
bilateral = 7:3), one (a mutation-positive parent) had
bilateral coloboma.
No plausibly pathogenic mutations or copy number
variants were identified in 36 cases. Of the 18 mutation-
positive cases, one had bi-allelic intragenic compound
heterozygous loss-of-function mutations in STRA6. Eleven
cases from nine families had heterozygous loss-of-func-
tions mutations affecting SOX2. Of these nine mutations,
two were transmitted from mother to child. In both these
families, analysis of the grandparental samples confirmed
that the mutation had occurred de novo in the mother.
Of the seven remaining SOX2 mutations, three occurred
de novo and four families did not have samples from
both parents available for analysis (Table 2).
Six cases from five families had heterozygous loss-
of-function mutations affecting OTX2. One of these
mutations was transmitted from mother to child. One
mutation occurred de novo in the affected individual and
in the remaining three families samples from both parents
were not available to determine inherited status. None of
the mutation-positive cases has associated facial clefts,
heart, or kidney anomalies (Table 3).
Segmental aneuploidy cases
SOX2 HI in CaseID 2850 resulted from a de novo 1.6Mb
genomic deletion (chr3:181,166,306–182,856,306; hg19)
(Fig. 1). This deletion encompasses six genes in addition
to SOX2 (including SOX2OT). This child has BA but sur-
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prisingly had normal development with no significant
extraocular features apart from a pineal cyst detected on
MRI at 4.5 years (Table 2). This suggests that the other
deleted genes have little or no haploinsufficient effect.
The HI score is designed to predict a haploinsufficient
effect of an individual gene. It is a combined metric
incorporating evolutionary conservation of the open read-
ing frame (ORF) and promoter, embryonic expression
and proximity to known haploinsufficient genes in pro-
tein–protein and probabilistic gene interaction networks
(Huang et al. 2010). The mean HI score of the genes in
the deletion in CaseID 2850 is 35.5% and ranges from
4.6%.(SOX2) to 69.7% (LAMP3).
This was due to a deletion in two other affected individ-
uals with OTX2 heterozygous loss-of-function (Fig. 1).
CaseID 3346 has a de novo 455Kb deletion (chr14:57,
154,247–57,609,247; hg19) which encompasses only OTX2
and the noncoding OTX2-AS1 gene. This child is develop-
ing well with normal speech (he started to speak at age
8 months, loves to sing) and motor development. Now at
age 2.6 years, he walks in areas known to him without any
problems, even up and down stairs. His otoacoustic emis-
sions (OAEs) and auditory brainstem responses (ABR) at
age 8 months indicate a normal hearing level in both ears
(Table 3). CaseID 3000 has a 6.5 Mb deletion
(chr14:57,024,247–63,524,247; hg19), however, both
parental samples were not available to determine de novo
status (Fig. 1). This deletion encompassed 36 genes in
addition to OTX2, including the known disease genes SIX6
(MIM# 606326 Microphthalmia with cataract 2 – dis-
cussed below), SIX1 (MIM# 601205 Brachiootic syndrome
3 and deafness, autosomal dominant 23), and PRKCH
(MIM# 605437 susceptibility to cerebral infarction). The
mean HI score of these genes is 40.5% and ranges from
0.5% (PPM1A) to 98.2% (C14orf101). This individual had
BA with significant developmental delay (Table 3). Brain-
stem auditory evoked response (BAER) recording at age
2 weeks and 3 months revealed normal responses between
80 and 60 dB. No reliable response could be documented
at 50 dB. She wore hearing aids till age 2 then she refused
to wear them. Repeated BAER recordings at age 2.5 years
showed good responses from 60 to 30 dB, which was con-
firmed at later age. The aCGH and FISH data for each of
the whole gene deletion mutations are shown in Figure S1.
SOX2 mutation cases
Consequence of mutations
Of the eight intragenic mutations in SOX2, five would
plausibly result in complete loss-of-function, four frame-
shift mutations, and one nonsense mutation (Tables 2 and
4). The remaining three mutations consisted of two mis-
sense changes, p.(His101Arg) and p.(Asp123Gly), and one
in-frame duplication, p.(Ala47dup). Residues Ala47 and
His101 lie within the HMG domain of SOX2 and both are
completely evolutionarily conserved to Drosophila mela-
nogaster SoxNeuro protein. The HMG domain is known
Table 1. Phenotype comparison of patients with and without identified mutations.
No mutation
identified OTX2 mutation SOX2 mutation STRA6 mutation Total
Molecular
diagnostic rate
Cases (families) 36 (36) 6 (5) 11 (9) 1 (1) 54 (51) 33.3 (29.4)
Male:Female 16:20 2:4 5:6 1:0 24:30 33.3:33.3
Ocular phenotype
Bilateral anophthalmia 3 3 5 1 12 75.0
Unilateral anophthalmia 23 2 52 0 30 23.3
Bilateral microphthalmia 3 0 0 0 3 0.0
Unilateral microphthalmia 7 0 0 0 7 0.0
Bilateral iris/chorio-retinal coloboma 0 0 12 0 12
Unaffected 0 12 0 0 12
No light perception in both eyes1 6 4 7 1 18 66.7
Extraocular abnormalities
Intracerebral MRI (excluding optic tract) 11/213 1/5 6/8 0/1
Facial clefts 6 0 0 0
Extremities 3 1 0 0
Ear abnormalities 5 1 0 0
Heart 5 0 0 0
Kidney 3 0 0 0
MRI, magnetic resonance imaging.
1At most recent visit.
2One parent (mother) affected.
3Available data.
18 ª 2013 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Genetic Causes of Anophthalmia C. Gerth-Kahlert et al.
to make direct contact with DNA, to bend the DNA
strand, and to mediate protein–protein interactions with
the cooperative binding partner transcription factor when
both are bound to the target site. Residue Ala47 lies within
the first alpha helix of the HMG domain. It is adjacent to
Asn46 which directly contacts DNA (Remenyi et al. 2003)
and is within a cluster of amino acids that mediate the
bending of the DNA strand (Scaffidi and Bianchi 2001).
Residue His101 lies immediately C-terminal of the third
alpha helical region but no specific role in the known
HMG functions has been defined for this residue. Aspartic
acid 123 (Asp123) lies outside the HMG domain in a
region of unknown function but this residue is completely
conserved within sequences from vertebrate species. The
identical nucleotide change causing the p.(Asp123Gly)
mutation here has been previously reported in a four-gen-
eration family with variable eye malformation (Mihelec
et al. 2009). These are clearly independent events as the
mutation in FamID 3227 has occurred de novo in the
affected mother. The chromatograms and pedigrees for
each of the intragenic mutations are shown in Figure S2.
Ocular phenotype
Each of the 10 SOX2 intragenic mutation cases reported
here is associated with severe ocular malformation
affecting at least one eye (Fig. 2). BA or UA with non-
functioning microphthalmia (UA-UM) was present in
four and two children, respectively. One of the children
with UA-UM (CaseID 3303) did fixate light and objects
as a small child but lost her vision due to sclerocornea
and severe microcornea. Two families with transmission
of a mutation from an affected mother to an affected
child (FamID 3432 and 3227) were identified. In FamID
3432, the mother and son both had UA, on the left and
right side, respectively. No ocular anomalies were seen in
the other eye. In FamID 3227, the mother had bilateral
iris and chorio-retinal coloboma with microcornea in the
more affected left eye. Her first daughter showed a nor-
mal eye examination. Her second daughter was born with
right anophthalmia and microphthalmia with microcror-
nea and chorio-retinal coloboma without fixation.
Extraocular phenotype and developmental data
The mean Z-scores for birth weight and birth occi-
pitofrontal circumference (OFC) were 0.12 and −1.03,
respectively. None of the birth weights were >2 SD from
the population mean. Two affected individuals (CaseID
2813 and 3303) had congenital microcephaly (birth OFC
Z-score 2 SD). Postnatal head growth was signifi-
cantly impaired with 6/8 cases having significant micro-
cephaly. The mean Z-scores for postnatal OFC, height,
and weight were −2.92, −0.85, and −1.16. Developmental
follow-up information was available in 8/10 affected indi-
viduals: four and seven cases had delayed speech and
motor development, respectively. None of the individuals
with SOX2 intragenic mutations show any significant
extracranial malformations or abnormalities.
Brain MRI was available in 7/10 cases with intragenic
mutations and one individual with a deletion. Of these
eight cases, six had reported abnormalities on the scan.
Four of eight cases had abnormal or dysmorphic midline
structure such as hypoplasic posterior corpus callosum,
septum pellucidum cyst, or cavum vergae. Fronto or fron-
to-temporal cerebral volume reduction but normally
developed corpus callosum and midline structures were
diagnosed in two of eight imaged children (Fig. 3).
OTX2 mutation cases
Consequence of mutations
Of the three different intragenic mutations in OTX2, two
were plausible loss-of-function mutations, both deletions
resulting in a frameshift within the ORF. The remaining
change is a missense mutation with the potential to alter
splicing, p.(Gln83His). Residue Gln83 lies within the home-
odomain of OTX2 between the second and third alpha
helical regions. This residue is conserved in all available
arthropod orthologs, the orthodenticle protein (Table 4).
Ocular phenotype
Three of the four individuals with intragenic mutations of
OTX2 had severe malformations affecting at least one eye
with two affected individuals showing complete blindness
(Fig. 4). One of the affected children showed BA (CaseID
2896). CaseID 2867 has right anophthalmia and microph-
thalmia, microcornea and retinal coloboma in the left eye.
The parents had observed some visual interaction in the
first months of life, however, these were lost because of
the severe ocular developmental anomalies. Her mother
(CaseID 3362), who carries the same mutation, demon-
strated a reduced vision due to amblyopia in the left eye
but no coloboma or axial length abnormalities. Unfortu-
nately, she did not consent for further investigations of ret-
inal function (electroretinogram) or morphology (optical
coherence tomography). CaseID 3197 had anophthalmia
in the right but no ocular abnormalities in the left eye.
Extraocular phenotype and developmental data
There was significant postnatal failure of head growth. The
mean Z-scores for birth weight and birth OFC were −0.56
and 0.02. The mean Z-scores for postnatal OFC, height,
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Table 2. Phenotype in patients with mutation in SOX2 gene.
FamID
3432 3194 2813 3171
CaseID 3432 3433 3194 2813 3171
Nucleotide change c.70_89del20 c.70_89del20 c.138_140dupTGC c.244_245delTT c.302A>G
Predicted
protein
change
or genomic
coordinates
p.(Asn24Argfs*65) p.(Ala47dup) p.(Leu82Valfs*13) p.(His101Arg)
Paternal/maternal
genotype
?/het (affected) wt/wt wt/wt ? (unavailable)/wt ? (unavailable)/wt
Ancestral
background
German German German German Croatian
Sex Male Female Male Male Male
Gestational age
(weeks+days)
37 41 42 38 + 6
Birth weight (g)
[Z-score]
3700 [0.3] 3830 [0.91] 3440 [−0.32] 2950 [−1.27]
Birth
occipitofrontal
circumference
(cm) [Z-score]
34.5 [−0.55] 33.7 [−1.18] 31.5 [−2.9]
Height (cm) [Z-score] 101 [−0.36] 178 [2.35] 110 [−1.2] 80 [−0.62] 70 [1.93]
Weight (kg) [Z-score] 18 57 [−1.97] 19 [−0.72] 10 [−1.27] 8.8 [1.43]
Age at growth
measurement
4 years 28.5 years 6 years 1.5 years 5 months
Occipitofrontal
circumference
(cm) at age
(years) [Z-score]
51 at 4 [−0.083] 45.5 at 4 [−4.5] 47.8 at 3.8 [−2.9]
Age at last
assessment
3.0 years 27.5 years 2 years 1.5 years 5 months
Ocular phenotype RE LE RE LE RE LE RE LE RE LE
Clinical
anophthalmia
x x x x x x x x
Microphthalmia
(axial length, mm)
Microcornea
(diameter, mm)
Sclerocornea
Coloboma
No abnormalities x x
Vision (decimal) No Fixation 0.7 No No No No No No No
Extraocular
abnormalities
Cerebral MRI
(at age)
Cavum vergae
(2.9 years)
Not done Small posterior
corpus callosum,
septum
pellucidum cyst
(3 months)
Fronto-temporal
cerebral volume
reduction
(3 months)
Small septum
pellucidum cyst
(2 months)
Hearing Normal? (OAEs
at age 3 negative
but had Eustachian
catarrh)
No test
available
OAEs at 6 years
normal
OAEs at birth and
age 4 years
normal
No test available
Speech
development
Delayed Reduced Good Severe delayed
(baby babble)
Motor
development
Delayed Spastic gait Walked at 2 years Walks with
support
Sleep Normal Normal Normal Wakes up at night
irregularly
The genomic sequence identifiers for SOX2 are NT_005612.15 GI:88966845. het, heterozygous; LE, left eye; MRI, magnetic resonance imaging;
OAEs, otoacustic emissions; RE, right eye; wt, wild-type; ?, unknown.
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3227 3303 3370 2850 3797
3227 3228 3303 3370 2850 3797
c.368A>G c.368A>G c.479_480
dupAC
c.841_851
del11insA
1.6 Mb del c277G>T
p.(Asp123Gly) p. (Ala161
Thrfs*4)
p. (Ala281
Argfs*87)
chr3:
182,649,000
–
184,339,000
(hg18)
p.(Glu93*)
wt/het (affected) wt/wt wt/wt ? (unavail-
able)/wt
wt/wt ?/wt
Austrian Austrian German German Kirgigistan/
Sachalin
German
Female Female Female Male Female Female
40 40 38 32 + 5 40 + 4 39 + 4
3250 [−0.34] 3050 [−0.79] 3090 [−0.7] 2000 [−0.18] 3840 [0.94] 4210 [1.7]
34 [−0.44] 32 [−2.06] 34 [−0.44] 35 [0.37]
85 [0.28] 167 [0.53] 110 [−2.1] 80 [−4.7] 120 [−1.8] 78 [−0.91]
10.9 [−0.58] 59 [−1.64] 20 [−0.96] 10 [−4.04] 23 [−1.1] 10 [−0.75]
1.9 years 34 years 7 years 3.4 years 8.5 years 1.5 years
48 at 3 [−1.9] 45.6 at 2
[−2.8]
46.0 at 5
[−4.4]
49 at 8.9
[−3.4]
44 at 1.5 [−3.36]
1.7 years 34 years 6 years 2.4 years 8.5 years 3 months
RE LE RE LE RE LE RE LE RE LE RE LE
x x x x x x x
x (18.5) x x (16.3 mm)
x (8.5) x x x (4 9 7)
x x
Retinal/
choroidal
Iris/retinal/
choroidal
Iris/retinal/
choroidal
No No
fixation
1.0 0.025 No No No No No No No LP
Normal
(10 days)
Not done Frontal
cerebral
volume
reduction
(5.8 years)
Not done Pineal cyst
(4.5 years)
Normal (1 month)
Normal Normal OAEs after
birth
abnormal
OAEs at birth
normal
OAEs at birth
normal
Normal
Normal Normal Severe
delayed
(only
mommy,
daddy)
Severe
delayed
(baby
babble)
Normal Normal
Delayed Normal Severe
delayed/
cannot sit
or walk
Severe
delayed/
cannot sit
or walk
Normal Normal
Normal Normal Normal Normal Normal Normal
Table 2. (continued).
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Table 3. Phenotype in patients with OTX2 mutation.
FamID
2896 3197 2867
CaseID 2896 3197 2867
Nucleotide change c.234delC c.249G>T c.276_294del19
Predicted
protein change
p.(Glu79Serfs*30) p.(Gln83His) or p.? p.(Lys92Asnfs*11)
Paternal/maternal genotype ?/wt wt/? wt/het (unaffected)
Ancestral background German Arabic Emirates German
Sex Male Female Female
Gestational age
(weeks + days)
41 + 5 36
Birth weight (g) [Z-score] 3870 [0.31] 2400 [−0.55]
Birth occipitofrontal
circumference
(cm) [Z-score]
34 [−0.95] 33 [−1.2]
Height (cm) [Z-score] 98 [−3.6] 142 [2.19] 113 [0.93]
Weight (kg) [Z-score] 13 [−4.3] 39 [1.8] 13 [−2.8]
Age at growth
measurement (years)
6 8.6 5
Occipitofrontal
circumference (cm)
at age (years) [Z-score]
48.9 at 5.7 [−2.7] No microcephaly 47.7 at 5 [−3.3]
Age at last
assessment (years)
6 8.6 6
Ocular phenotype RE LE RE LE RE LE
Clinical anophthalmia x x x x
Microphthalmia
(axial length, mm)
x (15.0)
Microcornea
(diameter, mm)
x (8.0)
Sclerocornea
Coloboma Retinal
Other No iris visible,
dysplastic
retina
No abnormalities x
Vision (decimal) No No No 1.0 No No
Extraocular abnormalities
Cerebral MRI (at age) No tractus opticus
(3 months)
Normal (6 months) Normal (3 months)
Hearing Right OAE at birth
normal
Normal Normal
Extremities Talipes equinovarus
Ear malformation Left microtia II°
Speech development Severe delayed
(baby babble)
Normal Delayed
Motor development Severe delayed,
does not crawl/
walk
Normal Delayed (walks short distances
w/o support
Sleep Sleep disorders
(abnormal SDSC)
Normal Sleep disorders (abnormal SDSC)
The genomic sequence identifiers for OTX2 are NT_026437.11 GI:51493278. ABR, auditory brainstem response; BERA, brainstem evoked response
audiometry; LE, left eye; MRI, magnetic resonance imaging; OAEs, otoacustic emissions; RE, right eye; SDSC, sleep disturbance scale for children.
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3346 3000
3362 3346 3000
c.276_294del19 455 kb deletion 6.5 Mb deletion
chr14:56,224,000-
56,679,000 (hg18)
chr14:56,094,000-
62,594,000 (hg18)
?/? wt/wt ?/?
German Polish German
Female Male Female
39 + 2 39
2920 [−0.98] 2810 [−1.01]
38 [2.2]
95 [0.9] 112 [−1.7]
12.5 [−0.88] 19 [−1.3]
2.6 7
49 at 3 [−1.7] 47 at 8.8 [−5.1]
34 1 8.7
RE LE RE LE RE LE
x x x x
Amblyopia
x
1.0 0.2 No No No No
Not done Normal (1 day) Small pituitary gland (4.7 years)
ABR and OAEs at 8 months normal BERA at age
2.5 years: good
responses from
60 to 30 db
Normal Normal Delayed
Normal Normal Delayed
Normal Normal Wakes up at night
Table 3. (continued).
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and weight were −3.2, −0.26, and −1.5. Two extraocular
malformations were observed: CaseID 2896 has unilateral
microtia (Fig. 3) and talipes equinovarus was observed in
CaseID 2867. Developmental assessment revealed delayed
speech and motor development in two of four children.
CaseID 2896 is the most severely affected as he does not
walk or crawl and has no receptive or expressive language
skills. He has been fed by gastrostomy tube since 4 years
of age. He has a very irregular sleep pattern and was trea-
ted with melatonin as a baby without success. His height
and weight is below the third percentile.
Cerebral MRIs were available in three of the four
affected individuals with OTX2 intragenic mutations, with
two of these showing no reported brain abnormality.
CaseID 2896 showed no optic tracks but the brain was
otherwise normal.
STRA6 mutation case
Consequence of mutation
CaseID 3279 has compound heterozygous mutations in
STRA6, with both mutations predicted to result in com-
plete loss of protein function. The exon 3 frameshift
mutation c.120dupG p.(Pro41Alafs*39) is maternally
inherited, and the exon 18 nonsense mutation c.1699C>T
p.(Arg567*) is paternally inherited.
Ocular phenotype
This boy is blind. He has bilateral apparent
anophthalmia with no cornea or sclera visible on clini-
cal examination. However, a small eye is visible on
MRI.
Extraocular phenotype and developmental data
He has normal motor development and age-appropriate
speech and language skills. He attends a normal school.
From a cardiorespiratory perspective, he has no chronic
symptomatology, indeed he can participate in physically
demanding sports. Following an episode of reactive air-
way disorder, he had a intensive pulmonary work up
and this revealed a restrictive respiratory disorder. The
pulmonary function test revealed reduced values (com-
pared with age-matched normative data pre- and post-
physical activity, respectively): total lung capacity (53%/
68%), inspiratory vital capacity (51%/50%), forced expi-
ratory volume after 1 sec (62%/57%), and maximal
expiratory flow after 75%, 50%, and 25% of forced vital
capacity.
The chest X-ray and computerized axial tomography
(CAT) scan revealed an asymmetric lung with reduced
volume in the left lung resulting in a left cardial cardiac
shift (Fig. 5).
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Figure 1. Schematic diagram showing three heterozygous deletions identified by array comparative genomic hybridization (CGH). (A) A de novo
1.69 Mb deletion in CaseID 2850 (chr3:182,649,000–184,339,000 equivalent to hg19 chr3:181,166,306–182,856,306) resulting in a loss of a
single copy of SOX2, shown in red. Deletions are marked by red bars. Genomic coordinates are based on the March 2006 Human Genome
Assembly (NCBI36/hg18). (B) A 6.5 Mb deletion in CaseID 3000 (chr14:56,094,000–62,594,000; equivalent to hg19 chr14:57,024,247–63,524-
247) and a de novo 455 kb deletion in CaseID 3346 (chr14:56,224,000–56,679,000; equivalent to hg19 chr14:57,154,247–57,609,247). Both
deletions resulted in a loss of a single copy of OTX2, shown in red.
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Discussion
It has been recognized for several years that heterozygous
loss-of-function mutations in SOX2 or OTX2, mostly
occurring de novo, are the major detectable genetic causes
of severe human eye malformations. More recently bi-
allelic mutations in STRA6 have emerged as a rare but
important cause of isolated anophthalmia in addition to
Figure 2. Portrait images of patients with a mutation in the SOX2 gene. Affected son at age 3 years and his mother with unilateral
anophthalmia at the right and left side (FamID 3432), respectively, are shown in the upper panel. The daughter with right anophthalmia, left
microphthalmia, and microcornea at age 5 months and her mother with bilateral irido and left > right chorio-retinal coloboma are shown in the
middle and fundus images in the left panel (CaseID 3327). Lower panel shows CaseID 3194 and CaseID 2850 at age 3 months and CaseID 3370
at 4 years (wears prosthetic shells) with bilateral anophthalmia, CaseID 3303 with right anophthalmia (wears prosthesis) and left microphthalmia,
sclerocornea and microcornea at age 4 years, CaseID 3797 with right anophthalmia and left microphthalmia, sclerocornea and microcornea at
age 3 months (small image).
Figure 3. Cerebral abnormalities associated with a mutation in SOX2 gene. Cavum vergae in a 3-year-old child with unilateral anophthalmia
(CaseID 3432; proton-weighted sagittal and transversal spine echo 3 mm scan). Pineal cyst in a child with bilateral anophthalmia (note: orbital
expander OU; CaseID 2850 at age 4.5 years; T2-weighted sagittal and T1-weighted transversal spine echo 3-mm scan). Small posterior part of the
corpus callosum and septum pellucidum cyst in a child with bilateral anophthalmia (CaseID 3194 at age 3 months; T2-weighted sagittal and
transversal spine echo 3-mm scan). Fronto-temporal cerebral volume reduction (T2-weighted native sagittal spine echo 2 mm and transversal
4-mm scan) in a 3-month-old boy with bilateral anophthalmia (CaseID 2813)
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the often lethal syndromal form. There have been many
other studies that have analyzed single genes or combina-
tions of genes in cohorts with various combinations of
eye malformations (summarized in Table S1). In order to
try to assess the relative contribution of each of the
known anophthalmia/severe microphthalmia genes (listed
in the Introduction), we analyzed a consecutive series of
referrals to a single tertiary ophthalmology center. In this
cohort, we have identified plausibly pathogenic mutations
in the SOX2, OTX2, and STRA6 genes which together
account for 15/51 (29.4%) of the probands: 9/51 (17.6%),
5/51 (9.8%), and 1/51 (1.96%) for each gene, respectively.
The proportions of affected individuals with SOX2 or
OTX2 mutations are higher than those reported in previ-
ous studies (Wyatt et al. 2008; Schneider et al. 2009;
Schilter et al. 2011), which probably reflects both the high
percentage of patients at the most severe end of the ocu-
lar malformation spectrum in the present study and our
inclusion of genome-wide aCGH to detect whole gene
deletions as part of the mutation analysis. In total, 75%
of bilateral and 20.7% of UA cases in our cohort are
explained by mutations in these three genes.
Two examples of familial transmission of a SOX2
mutation were identified. A SOX2 missense mutation,
Figure 4. Portrait images of the children with mutations in the OTX2 gene: CaseID 2867 at age 1 year with right anophthalmia (wears prosthetic
shell) and left microphthalmia and microcornea. CaseID 2896 with bilateral anophthalmia and left microtia at age 3 months and age 6 years
(wears prosthetic shells both sides; upper panel). CaseID 3000 at age 9 years with bilateral anophthalmia (wears prosthetic shell on the left side).
CaseID 3197 with right anophthalmia at age 3 months. CaseID 3346 at age 1 year with bilateral anophthalmia (wears prosthetic shell on the
right side).
Figure 5. Chest X-ray (anterior–posterior scan) and chest CAT scan (axial and anterior–posterior scan) of CaseID 3279 with STRA6 mutation
show an elevated diaphragm, a right–left lung asymmetry with reduced lung volume in the left lung, and left-shifted heart.
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c.368A>G p.(Asp123Gly), in one child with anophthal-
mia/microphthalmia that was inherited from her mother,
who has bilateral chorio-retinal coloboma and microcor-
nea in one eye. This mutation has arisen de novo in the
mother. The mutation appears to be nonmosaic in the
mother based on the observation of an equal ratio of
mutant to nonmutant sequence on the chromatogram
from blood DNA. We have, however, not been able to
assess this ratio in other tissues of different embryonic
origin. Remarkably, exactly the same mutation has been
shown to segregate in a four-generation family of Austra-
lian descent, with a wide phenotypic spectrum ranging
from iris hypoplasia to BA (Mihelec et al. 2009). There is
no known function for this residue although it is located
in a region of the protein that has been termed the part-
ner factor domain (Kamachi et al. 1999). The second
family is remarkable; both the mother and son have UA
with a normal contralateral eye and both carry a frame-
shift mutation in SOX2, c.70_89del20 p.(Asn24Argfs*65),
occurring before the sequence encoding the HMG
domain. This mutation is apparently nonmosaic based on
the mutant:nonmutant allele ratio in the sequencing chro-
matogram from blood DNA. The mutation has occurred
de novo in the mother. This appears to represent the first
known transmission of a nonmosaic complete loss-
of-function allele in SOX2.
While familial recurrence of SOX2 associated ocular
malformation has been reported (Faivre et al. 2006;
Schneider et al. 2008; Mihelec et al. 2009; Stark et al.
2011), these have been either missense mutations that
may represent hypomorphic alleles or have been shown
to be mosaic in the “carrier” mother. The first description
identified a SOX2 missense mutation in two children
(anophthalmia/cryptophthalmos, severe hydrocephalus,
and corpus callosum agenesis in a terminated fetus and
BA in one sibling). Their unaffected mother was found to
be mosaic for the same mutation resulting in this “pseudo
recessive” pattern of inheritance (Faivre et al. 2006). Simi-
larly, two daughters, anophthalmia and microphthalmia
in one and BA in the other associated with partial agene-
sis of the corpus callosum, were born to a phenotypically
normal mother who carries the same SOX2 deletion in a
mosaic state (Schneider et al. 2008). It is interesting to
note that all transmissions of mutant SOX2 alleles have
been from the mother, which may suggest that female
gametogenesis is more tolerant of reduced SOX2 dosage
than is spermatogenesis. This notion is supported by the
finding of a reduction in male but not female fertility in
mice that carry a heterozygous loss-of-function SOX2
allele (Avilion et al. 2003).
Identifying nonocular malformations that are nonran-
domly associated with mutations in “eye malformation”
genes may give clues to the specific developmental mecha-
nisms that are disrupted. In our study, we identified one
individual with an OTX2 mutation associated with unilat-
eral microtia. Recently another unpublished child with
bilateral microtia associated with BA has been identified
in our laboratory (K. M. Girisha, unpubl. data), suggest-
ing that this is a genuine association.
Intracerebral abnormalities are described in 30% of
patients with anophthalmia-plus syndrome (reviewed in
Makhoul et al. [2007]). SOX2 expression plays a crucial
role in brain development, in particular the pituitary
gland and hippocampal formation (Sisodiya et al. 2006;
Table 4. Predicted consequences of identified missense mutations.
Gene
Protein
change
Align-
GVGD
class
PolyPhen-2
(score) SIFT (score)
Mutation
Taster (P-value)
SSF
(scale 1–100,
wt:mut
[% diff])
MaxEnt
(scale 1–12,
wt:mut
[% diff])
NNSPLICE
(scale 0–1,
wt:mut
[% diff])
HSF
(scale
1–100,
wt:mut
[% diff])
SOX2 p.(His101Arg) C25 Probably
damaging
(0.996)
Deleterious
(0.00)
Disease
causing (1.0)
SOX2 p.(Asp123Gly) C65 Possibly
damaging
(0.616)
Deleterious
(0.00)
Disease
causing (1.0)
OTX2 p.(Gln83His) C15 Probably
damaging
(1.000)
Deleterious
(0.00)
Disease
causing (1.0)
84.9:72.3
(−14.9%)
9.5:2.2
(−77.2%)
0.75:0 89.7:78.9
(−12.1%)
wt:mut, the ratio of scores between wild-type and mutant alleles, respectively; % diff, the percentage difference between the wild-type and
mutant allele score. Align-GVGD, align with Grantham variation (GV), Grantham deviation (GD); HSF, human splicing finder; MaxEnt, maximum
entropy modeling of short sequence motifs; NNSPLICE, neural network splice site analysis; PolyPhen-2, polymorphism phenotyping v2; SIFT,
sorting intolerant from tolerant; SSF, splicing sequences finder.
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Kelberman et al. 2008; Alatzoglou et al. 2011). Sox2
expression was identified in the forebrain, within Rathke’s
pouch and throughout the anterior but not posterior
pituitary development, in the hypothalamus, and within
neural ectoderm during human embryonic development
(Kelberman et al. 2008), which becomes more restricted
to the ventricular zone cells at midgestation (Sisodiya
et al. 2006). Individuals with SOX2 mutations are
reported to have intracerebral anomalies including
mesial-temporal malformation, hypoplasia or ectopia of
the anterior pituitary gland or corpus callosum hypoplasia
(Fantes et al. 2003; Ragge et al. 2005b; Sisodiya et al.
2006; Kelberman et al. 2008; Schneider et al. 2008). Ala-
tzoglou et al. (2011) reported two children with SOX2
HI, who developed slowly progressing hypothalamo-pitu-
itary tumors.
Mutations in SOX2 were associated with central ner-
vous system (CNS) abnormalities outside the optic tract
in all but two of the affected individuals on whom neu-
roimaging was available. Cerebral MRI scans had not
been performed on three of the affected individuals, two
of these were affected mothers. Most of the affected chil-
dren showed midline anomalies such as cysts in the sep-
tum pellucidum or pineal gland, small corpus callosum
or cavum vergae. Pituitary functional testing is not avail-
able from the children with SOX2 mutations. Several chil-
dren have growth measurement that map below the third
percentile for height and or weight, indicating possible
hormonal deficiency.
Mutations in OTX2 are associated with pituitary struc-
tural abnormalities such as anterior hypoplastic and ecto-
pic or absent posterior pituitary gland (Nolen et al. 2006;
Diaczok et al. 2008; Tajima et al. 2009; Dateki et al. 2010;
Schilter et al. 2011) and/or hormone deficiency (Nolen
et al. 2006; Dateki et al. 2008, 2010; Diaczok et al. 2008;
Tajima et al. 2009; Schilter et al. 2011). Partial or global
growth hormone deficiency is the most common observed
hormonal abnormality in patients with OTX2 mutations.
Other cerebral abnormalities associated with OTX2 muta-
tions are corpus callosum hypoplasia (Ragge et al. 2005a;
Nolen et al. 2006), abnormal hippocampus (Ragge et al.
2005a; Dateki et al. 2008), ventriculomegaly (Ragge et al.
2005a; Nolen et al. 2006), or absent pineal gland (Hen-
derson et al. 2007). One of the five children reported in
our group showed a small pituitary gland. Cerebral MRI
was performed in this child at age 4.7 years in compari-
son with the MRI scans performed between ages one day
to 6 months in the other four children with OTX2 muta-
tions. Structural pituitary abnormalities in those children
cannot be entirely ruled out because of the early age of
imaging. Pituitary function is not available in our patient
group. However, one child is below the third percentile
for growth and weight, and two other children are below
the third percentile weight. It is important that a high
index of suspicion for functional pituitary anomalies is
maintained for children with loss-of-function mutations
in both OTX2 and SOX2.
The absence of any intellectual disability and the rela-
tively mild pulmonary phenotype in the boy with a com-
pound heterozygous mutation in STRA6 is interesting.
This confirms that STRA6 should be considered a rare
but important cause of isolated ocular malformations in
addition to the severe lethal multisystem disorders that
were observed in the originally reported cases.
No mutations were identified in five of the eight genes
screened: PAX6 (paired domain), BMP4, SMOC1, FOXE3,
and RAX. This may relate to the size of the cohort that
was screened or, for the autosomal recessive loci (SMOC1,
FOXE3, and RAX), population differences in disease allele
frequencies and/or rates of consanguinity. While it is dif-
ficult to make firm conclusion, based on the published
literature (summarized in Table S1) and our own unpub-
lished data, BMP4 and RAX, in particular, appear to be
very rare causes of anophthalmia.
This study does have implications for the clinical
molecular approach to the diagnosis of individuals with
severe eye malformations. A screen for heterozygous
loss-of-function mutations in either SOX2 or OTX2
should clearly be the first line test that will have a sig-
nificant detection rate in cases of anophthalmia. It
would also be reasonable to include STRA6 in the initial
analysis. However, different eye malformations are likely
to require specific mutation screening strategies. None of
these genes screened here represent significant causative
loci for ocular coloboma, the single most common
major eye malformation (D. R. FitzPatrick, unpubl.
data). This may reflect genuine differences of the devel-
opmental pathology between these apparently overlap-
ping classes of eye malformation but useful analysis
must await the identification of the major causative loci
for coloboma.
There remain many individuals in this cohort for
whom we have not been able to identify a specific genetic
cause. Whole genome and exome sequencing will be an
important next step to identify new genes and/or genetic
mechanisms that may account for this very interesting
and important group of malformations.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Array CGH identified three heterozygous dele-
tions encompassing the genes OTX2 and SOX2. (A) Nor-
malised log2 ratios indicating two deletions of OTX2 in
CaseID 3000 and CaseID 3346. (B) Normalised log2
ratios showing a deletion of SOX2 in CaseID 2850.
Figure S2. Intragenic mutations identified in 12 families.
A pedigree, mutation summary, and sequence chromato-
gram(s) are shown for each family with an identified
intragenic mutation: eight SOX2 mutation families, three
OTX2 mutation families and one STRA6 mutation family.
Excepting the parents in the recessive STRA6 family, all
individuals carrying a mutation are indicated by CaseID.
For each pedigree all known affected individuals are
shown, and all individuals shown were tested for the
identified mutation. Unfilled symbols containing N repre-
sent unaffected individual with wild-type sequence; solid
filled symbol, affected individual carrying mutation(s);
dotted filled symbol, unaffected individual carrying muta-
tion. All sequence chromatograms show the forward read,
except for FamID 2867 where the reverse read is shown
for clarity of data in a Gln (Q) repeat region. The wild-
type reference sequence used for each gene is as follows:
SOX2, NT_005612.15 GI:88966845; OTX2, NT_026437.11
GI:51493278; STRA6, NG_009207.1 GI:219275560.
Table S1. Reported studies.
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